. 2021 Feb 1;15:592975. doi: 10.3389/fnhum.2021.592975

TABLE 1.

Demographic and clinical characteristics of participants.

	LHD group (n = 38)	RHD group (n = 29)	p-Value
Gender (M/F)	30/8	21/8	0.534^a
Age: Mean ± SD	60.1 (10.4)	63.7 (10.0)	0.057^c
Dominance (R/L/A)	36/2/0	25/3/1	0.366^a
Stroke type (I/H/I > H)	22/16/0	20/8/1	0.273^a
TAO months: Mean ± SD	28.9 (14.6)	28.7 (10.9)	0.939^b
Lesion volume (cc): Mean ± SD	25.4 (25.2)	21.5 (28.0)	0.140^c
FMA-LE: X/32: Mean ± SD	26.6 (5.3)	26.1 (7.1)	0.784^b
3MWT (m/s): Mean ± SD	0.8 (0.3)	0.8 (0.4)	0.970^b
Sensation (x/12): Mean ± SD	9.9 (3.2)	10.3 (2.5)	0.928^c
*Use of assistive device for walking (no/yes)	26/12	21/8	0.723^a

LHD, left hemisphere damage; RHD, right hemisphere damage; gender: M, male; F, female; dominance: R, right; L, left, A, ambidextrous; stroke type: I, ischemic; H, hemorrhagic, I > H, ischemic with hemorrhagic transformation; TAO, time after stroke onset; FMA-LE, Fugl-Meyer assessment lower extremity; 3MWT, 3 m walk test; a, Chi-Square test; b, t-test; c, Mann–Whitney test. *Assistive device refers in most cases to an ankle-foot orthosis and/or cane. FMA-LE, 3MWT and sensation were tested in the chronic phase (time after stroke onset more than 1 year, as mentioned in “TAO months”).